Oct 20, 2018 10:45am EDT Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress
Oct 08, 2018 6:10pm EDT Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress
Sep 07, 2018 1:14pm EDT Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary Shares
Sep 05, 2018 7:30am EDT Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares
Aug 15, 2018 7:30am EDT Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort
Aug 02, 2018 7:30am EDT Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update
Jul 26, 2018 1:18pm EDT Adaptimmune to Report Second Quarter 2018 Financial Results and Business Update on Thursday August 2, 2018
Jul 24, 2018 7:30am EDT GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK
Jul 18, 2018 7:29am EDT Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts
Jun 11, 2018 7:30am EDT Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self‑renewing, and Capable of Persistent Anti-Tumor Effects
